Safety and Feasibility of Reduced-Frequency Dosing of Axatilimab in Patients Treated in the AGAVE-201 Study
Blood Advances | October 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available
10.1182/bloodadvances.2026021323
| PMID 42913434